Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Complications of Combined Radiotherapy and Chemotherapy.

Seminars in radiation oncology

von der Maase H.
PMID: 10717094
Semin Radiat Oncol. 1994 Apr;4(2):81-94. doi: 10.1053/SRAO00400081.

The radiation-modifying effect of cancer chemotherapeutic drugs is reviewed based on experimental studies covering skin, esophagus, intestinal tract, lungs, kidney, bladder, testis, and hematopoietic tissue. The results obtained in experimental studies have, whenever possible, been compared with observations of...

Cite
von der Maase H. Complications of Combined Radiotherapy and Chemotherapy. Semin Radiat Oncol. 1994;4(2):81-94doi: 10.1053/SRAO00400081.
von der Maase H. (1994). Complications of Combined Radiotherapy and Chemotherapy. Seminars in radiation oncology, 4(2), 81-94. https://doi.org/10.1053/SRAO00400081
von der Maase H. "Complications of Combined Radiotherapy and Chemotherapy." Seminars in radiation oncology vol. 4,2 (1994): 81-94. doi: https://doi.org/10.1053/SRAO00400081
von der Maase H. Complications of Combined Radiotherapy and Chemotherapy. Semin Radiat Oncol. 1994 Apr;4(2):81-94. doi: 10.1053/SRAO00400081. PMID: 10717094.
Copy Download .nbib Format: NLM
The DOMUS study protocol: a randomized clinical trial of accelerated transition from oncological treatment to specialized palliative care at home.

BMC palliative care

Nordly M, Benthien KS, Von Der Maase H, Johansen C, Kruse M, Timm H, Vadstrup ES, Kurita GP, von Heymann-Horan AB, Sjøgren P.
PMID: 25242890
BMC Palliat Care. 2014 Sep 09;13:44. doi: 10.1186/1472-684X-13-44. eCollection 2014.

BACKGROUND: The focus of Specialized Palliative Care (SPC) is to improve care for patients with incurable diseases and their families, which includes the opportunity to make their own choice of place of care and ultimately place of death. The...

Cite
Nordly M, Benthien KS, Von Der Maase H, et al. The DOMUS study protocol: a randomized clinical trial of accelerated transition from oncological treatment to specialized palliative care at home. BMC Palliat Care. 2014;13:44doi: 10.1186/1472-684X-13-44.
Nordly, M., Benthien, K. S., Von Der Maase, H., Johansen, C., Kruse, M., Timm, H., Vadstrup, E. S., Kurita, G. P., von Heymann-Horan, A. B., & Sjøgren, P. (2014). The DOMUS study protocol: a randomized clinical trial of accelerated transition from oncological treatment to specialized palliative care at home. BMC palliative care, 1344. https://doi.org/10.1186/1472-684X-13-44
Nordly, Mie, et al. "The DOMUS study protocol: a randomized clinical trial of accelerated transition from oncological treatment to specialized palliative care at home." BMC palliative care vol. 13 (2014): 44. doi: https://doi.org/10.1186/1472-684X-13-44
Nordly M, Benthien KS, Von Der Maase H, Johansen C, Kruse M, Timm H, Vadstrup ES, Kurita GP, von Heymann-Horan AB, Sjøgren P. The DOMUS study protocol: a randomized clinical trial of accelerated transition from oncological treatment to specialized palliative care at home. BMC Palliat Care. 2014 Sep 09;13:44. doi: 10.1186/1472-684X-13-44. eCollection 2014. PMID: 25242890; PMCID: PMC4169691.
Copy Download .nbib Format: NLM
A Minimal Theory of Creative Ability.

Journal of Intelligence

Stevenson C, Baas M, van der Maas H.
PMID: 33669216
J Intell. 2021 Feb 16;9(1). doi: 10.3390/jintelligence9010009.

Despite decades of extensive research on creativity, the field still combats psychometric problems when measuring individual differences in creative ability and people's potential to achieve real-world outcomes that are both original and useful. We think these seemingly technical issues...

Cite
Stevenson C, Baas M, van der Maas H. A Minimal Theory of Creative Ability. J Intell. 2021;9(1)doi: 10.3390/jintelligence9010009.
Stevenson, C., Baas, M., & van der Maas, H. (2021). A Minimal Theory of Creative Ability. Journal of Intelligence, 9(1), . https://doi.org/10.3390/jintelligence9010009
Stevenson, Claire, et al. "A Minimal Theory of Creative Ability." Journal of Intelligence vol. 9,1 (2021). doi: https://doi.org/10.3390/jintelligence9010009
Stevenson C, Baas M, van der Maas H. A Minimal Theory of Creative Ability. J Intell. 2021 Feb 16;9(1). doi: 10.3390/jintelligence9010009. PMID: 33669216; PMCID: PMC8006236.
Copy Download .nbib Format: NLM
[Oncologic treatment].

Ugeskrift for laeger

von der Maase H.
PMID: 12082846
Ugeskr Laeger. 2002 Jun 03;164(23):2999.

No abstract available.

Cite
von der Maase H. Onkologisk behandling. [Oncologic treatment]. Ugeskr Laeger. 2002;164(23):2999
von der Maase, H. (2002). Onkologisk behandling. [Oncologic treatment]. Ugeskrift for laeger, 164(23), 2999.
von der Maase, Hans. "Onkologisk behandling." [Oncologic treatment]. Ugeskrift for laeger vol. 164,23 (2002): 2999.
von der Maase H. Onkologisk behandling. [Oncologic treatment]. Ugeskr Laeger. 2002 Jun 03;164(23):2999. Danish. PMID: 12082846.
Copy Download .nbib Format: NLM
[Non-surgical treatment of cancer at the turn of century].

Ugeskrift for laeger

von der Maase H.
PMID: 10603748
Ugeskr Laeger. 1999 Nov 08;161(45):6159.

No abstract available.

Cite
von der Maase H. Non-kirurgisk behandling af kraeft ved årtusindskiftet. [Non-surgical treatment of cancer at the turn of century]. Ugeskr Laeger. 1999;161(45):6159
von der Maase, H. (1999). Non-kirurgisk behandling af kraeft ved årtusindskiftet. [Non-surgical treatment of cancer at the turn of century]. Ugeskrift for laeger, 161(45), 6159.
von der Maase, H. "Non-kirurgisk behandling af kraeft ved årtusindskiftet." [Non-surgical treatment of cancer at the turn of century]. Ugeskrift for laeger vol. 161,45 (1999): 6159.
von der Maase H. Non-kirurgisk behandling af kraeft ved årtusindskiftet. [Non-surgical treatment of cancer at the turn of century]. Ugeskr Laeger. 1999 Nov 08;161(45):6159. Danish. PMID: 10603748.
Copy Download .nbib Format: NLM
Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.

Cancers

Dohn LH, Thind P, Salling L, Lindberg H, Oersted S, Christensen IJ, Laerum OD, Illemann M, von der Maase H, Høyer-Hansen G, Pappot H.
PMID: 34069121
Cancers (Basel). 2021 May 14;13(10). doi: 10.3390/cancers13102377.

Urothelial carcinoma of the bladder is a highly aggressive disease characterised by a very heterogeneous clinical outcome. Despite cystectomy, patients still have a high recurrence risk and shortened survival. Urokinase-type plasminogen activator receptor (uPAR) is present in tumour tissue...

Cite
Dohn LH, Thind P, Salling L, et al. Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder. Cancers (Basel). 2021;13(10)doi: 10.3390/cancers13102377.
Dohn, L. H., Thind, P., Salling, L., Lindberg, H., Oersted, S., Christensen, I. J., Laerum, O. D., Illemann, M., von der Maase, H., Høyer-Hansen, G., & Pappot, H. (2021). Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder. Cancers, 13(10), . https://doi.org/10.3390/cancers13102377
Dohn, Line H, et al. "Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder." Cancers vol. 13,10 (2021). doi: https://doi.org/10.3390/cancers13102377
Dohn LH, Thind P, Salling L, Lindberg H, Oersted S, Christensen IJ, Laerum OD, Illemann M, von der Maase H, Høyer-Hansen G, Pappot H. Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder. Cancers (Basel). 2021 May 14;13(10). doi: 10.3390/cancers13102377. PMID: 34069121; PMCID: PMC8156453.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries